Latest news

Over 40 managers from Alvotech and Alvogen made their way to the CPhI in Frankurt last week. The CPhI is one of the most important events for the industry in...

Alvotech has appointed Rasmus Rojkjaer as Chief Executive Officer, succeeding Eef Schimmelpennink, who has stepped down from his role. As CEO of Alvotech, Rasmus brings over 20 years of global...

Over 40 managers from Alvotech and Alvogen attended CPhI last week for the fifth time. CPhI is the premiere event of the year in the pharma industry calendar and the...

The latest issue of Generics bulletin, an international trade magazine, which covers news in the global generic medicines and biosimilars markets with subscribers in over 60 countries, features an in-depth...

Alvotech, today announces the opening of a new state-of-the-art facility, dedicated to the development and manufacturing of biosimilar monoclonal antibodies (“mAbs”). The opening of this industry leading biologics manufacturing plant...

Alvotech today announced that it has closed on the acquisition of ​Baliopharm GmbH, a German biopharmaceutical development company, previously a subsidiary of Baliopharm AG. The acquisition provides Alvotech with complimentary...

Alvotech is proud to announce Richard Davies as the Chairman of the Board of Directors. Richard has over 25 years of experience in the pharmaceutical and biotechnology industry. He is...

This promises to be a busy and exciting fall for Alvotech. Once more it will be participating in the world’s largest pharmaceutical fair, CPhI, which this year is being hosted...

Alvotech has already recruited more than 40 new science professionals to its team, since it first broke ground in November 2013 with the building of a vast state-of-the-art development and...

Alvotech, a global biopharmaceutical company in the biosimilar monoclonal antibody market, announces that Dr. Jennifer Hunt has been appointed as Vice President of Operations. Dr. Jennifer Hunt will be responsible...

Alvotech will be recruiting 50 new employees for its new state-of-the-art biomanufacturing facility in the science park of the University of Iceland in Reykjavik over the coming months. Some...

For the second year in a row, Alvogen stood out in the crowd at the annual CPhI event in October, which this year was hosted in Paris, France. CPhI is...

Alvotech, a powerful new player in the field of biopharmaceuticals and Finesse Solutions, Inc. ("Finesse"), today announce that they have entered into a partnership that will provide Alvotech with world-class,...

Alvotech is a powerful new player in the field of biopharmaceuticals and is currently looking for team players. Would you like to become a part of the Alvotech team and...

Alvotech, a powerful new player in the field of biopharmaceuticals, today announced plans to invest $250 million in the development and manufacturing of a portfolio of biosimilar monoclonal antibodies. -...